Display options
Cite
Kroschinsky F, Middeke JM, Janz M, et al. Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma. Invest New Drugs. 2021;39(1):285-286doi: 10.1007/s10637-020-00964-9.
Kroschinsky, F., Middeke, J. M., Janz, M., Lenz, G., Witzens-Harig, M., Bouabdallah, R., La Rosée, P., Viardot, A., Salles, G., Kim, S. J., Kim, T. M., Ottmann, O., Chromik, J., Quinson, A. M., von Wangenheim, U., Burkard, U., Berk, A., & Schmitz, N. (2021). Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma. Investigational new drugs, 39(1), 285-286. https://doi.org/10.1007/s10637-020-00964-9
Kroschinsky, Frank, et al. "Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma." Investigational new drugs vol. 39,1 (2021): 285-286. doi: https://doi.org/10.1007/s10637-020-00964-9
Kroschinsky F, Middeke JM, Janz M, Lenz G, Witzens-Harig M, Bouabdallah R, La Rosée P, Viardot A, Salles G, Kim SJ, Kim TM, Ottmann O, Chromik J, Quinson AM, von Wangenheim U, Burkard U, Berk A, Schmitz N. Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma. Invest New Drugs. 2021 Feb;39(1):285-286. doi: 10.1007/s10637-020-00964-9. PMID: 32578153; PMCID: PMC8025277.
Copy Download .nbib Format: NLM
Share it on

Invest New Drugs. 2021 Feb;39(1):285-286. doi: 10.1007/s10637-020-00964-9.

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma.

Investigational new drugs

Frank Kroschinsky, Jan Moritz Middeke, Martin Janz, Georg Lenz, Mathias Witzens-Harig, Reda Bouabdallah, Paul La Rosée, Andreas Viardot, Gilles Salles, Seok Jin Kim, Tae Min Kim, Oliver Ottmann, Joerg Chromik, Anne-Marie Quinson, Ute von Wangenheim, Ute Burkard, Andreas Berk, Norbert Schmitz

Affiliations

  1. Medical Department I, University Hospital at the Technical University of Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
  2. Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Robert-Rössle-Straße 10, 13125, Berlin, Germany.
  3. Department of Hematology and Oncology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
  4. Internal Medicine V: Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 672, 69120, Heidelberg, Germany.
  5. Department ofHematology, Institute Paoli Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.
  6. Klinik für Innere Medizin II, Universitätsklinikum, Jena, Germany.
  7. Klinik für Innere Medizin II, Schwarzwald-Baar-Klinikum, Villingen-Schweningen, Germany.
  8. Department of Internal Medicine III, University Hospital of Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany.
  9. Department of Hematology, University Hospital of South Lyon, 165 Chemin du Grand Revoyet, 69310, Pierre-Bénite, France.
  10. Division of Haematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Irwon-dong, Gangnam-gu, Seoul, South Korea.
  11. Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-Ro Jongno-Gu, Seoul, 03080, South Korea.
  12. Cancer Research Institute, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, South Korea.
  13. Division of Cancer and Genetics, Department of Haematology, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK.
  14. Universitätsklinikum Frankfurt, Johann-Wolfgang-Goethe-Universität, Theodor-W.-Adorno-Platz 1, 60323, Frankfurt, Germany.
  15. Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, Ridgefield, CT, 06877, USA.
  16. Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397, Biberach an der Riß, Germany.
  17. ClinTriCare GmbH & Co. KG, Untere Illereicher Str. 10, 89281, Altenstadt, Germany.
  18. Department of Hematology and Oncology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany. [email protected].

PMID: 32578153 PMCID: PMC8025277 DOI: 10.1007/s10637-020-00964-9

[No abstract available.]

Publication Types